PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27838126-3	2017	OBJECTIVE: To determine whether derivatives of tetracaine, a local anesthetic drug with known RyR2 inhibiting action, could prevent CPVT induction by suppression of RyR2-mediated SR Ca2+ leak.	Tetracaine	47-57	ryanodine receptor 2, cardiac	Mus musculus	94-98	
18598963-5	2008	Right atrial programmed stimulation was performed before and after injection of RyR2 antagonist tetracaine (0.5 mg/kg).	Tetracaine	96-106	ryanodine receptor 2, cardiac	Mus musculus	80-84	
29248564-3	2018	OBJECTIVE: Determine whether the tetracaine-derivative compound EL20 inhibits abnormal Ca2+ release from RyR2 in a CPVT model and investigate the underlying mechanism of inhibition.	Tetracaine	33-43	ryanodine receptor 2, cardiac	Mus musculus	105-109	
20595652-9	2010	In contrast, the RyR2 blocker tetracaine was equally efficacious in mutant Purkinje cells and ventricular myocytes.	Tetracaine	30-40	ryanodine receptor 2, cardiac	Mus musculus	17-21	
19835880-9	2010	In lipid bilayers, flecainide inhibited RyR2 channels by open state block, whereas tetracaine primarily prolonged RyR2 closed times.	Tetracaine	83-93	ryanodine receptor 2, cardiac	Mus musculus	114-118	
34110090-4	2021	Recently, it was demonstrated that tetracaine derivative EL20 specifically inhibits mutant RyR2, normalizes Ca2+ handling and suppresses arrhythmias in a CPVT mouse model.	Tetracaine	35-45	ryanodine receptor 2, cardiac	Mus musculus	91-95	
30261161-14	2018	Furthermore, in WT CMs pretreated with RyR2 blocker tetracaine, IP3 and anti-PLB Fab still increased the magnitude of nuclear Ca2+ release but failed to regenerate SCWs.	Tetracaine	52-62	ryanodine receptor 2, cardiac	Mus musculus	39-43	
29401432-10	2018	Time-lapse total internal reflection fluorescence imaging revealed dynamic movements of GFP-RyR2 clusters in the periphery, which were affected by external Ca2+ and RyR2 activator (caffeine) and inhibitor (tetracaine), but little detectable movement of GFP-RyR2 clusters in the interior.	Tetracaine	206-216	ryanodine receptor 2, cardiac	Mus musculus	92-96	
29401432-10	2018	Time-lapse total internal reflection fluorescence imaging revealed dynamic movements of GFP-RyR2 clusters in the periphery, which were affected by external Ca2+ and RyR2 activator (caffeine) and inhibitor (tetracaine), but little detectable movement of GFP-RyR2 clusters in the interior.	Tetracaine	206-216	ryanodine receptor 2, cardiac	Mus musculus	165-169	
29401432-10	2018	Time-lapse total internal reflection fluorescence imaging revealed dynamic movements of GFP-RyR2 clusters in the periphery, which were affected by external Ca2+ and RyR2 activator (caffeine) and inhibitor (tetracaine), but little detectable movement of GFP-RyR2 clusters in the interior.	Tetracaine	206-216	ryanodine receptor 2, cardiac	Mus musculus	165-169	
27838126-3	2017	OBJECTIVE: To determine whether derivatives of tetracaine, a local anesthetic drug with known RyR2 inhibiting action, could prevent CPVT induction by suppression of RyR2-mediated SR Ca2+ leak.	Tetracaine	47-57	ryanodine receptor 2, cardiac	Mus musculus	165-169	
27838126-9	2017	CONCLUSIONS: Tetracaine derivatives represent a novel class of RyR2 stabilizing drugs that could be used for the treatment of the potentially fatal disorder catecholaminergic polymorphic ventricular tachycardia.	Tetracaine	13-23	ryanodine receptor 2, cardiac	Mus musculus	63-67